Ceramide Synthase 2 (CERS2) ELISA Kits

CERS2 encodes a protein that has sequence similarity to yeast longevity assurance gene 1. Additionally we are shipping Ceramide Synthase 2 Antibodies (73) and Ceramide Synthase 2 Proteins (6) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
CERS2 29956 Q96G23
Anti-Mouse CERS2 CERS2 76893 Q924Z4
Anti-Rat CERS2 CERS2 310667  
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top Ceramide Synthase 2 ELISA Kits at antibodies-online.com

Showing 1 out of 7 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Delivery Price Details
Human 0.058 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests 13 to 16 Days
$810.53
Details

More ELISA Kits for Ceramide Synthase 2 Interaction Partners

Human Ceramide Synthase 2 (CERS2) interaction partners

  1. Data show that mRNA expression of Cer metabolizing enzyme CERS2 was significantly increased in multiple sclerosis (MS) patients.

  2. G0/G1 ratio in LASS2/TMSG1 S248A group was obviously higher than that in LASS2/TMSG1 wild group

  3. Study findings suggest that LASS2 inhibits proliferation and induces apoptosis in HepG2 hepatoblastoma cells through the mitochondrial apoptotic, NFkappaB and cell cycle signaling pathways.

  4. results indicate that miR-3622a promotes the proliferation and invasion of bladder cancer cells by downregulating LASS2.

  5. As potential molecular markers for bladder carcinoma, both TWIST1 and LASS2 transcripts seem to play role during the tumorigenesis and development of bladder cancer.

  6. Results show that silencing of ATP6V0C in highly metastatic prostate cancer (PC) cell lines, inhibited V-ATPase activity, which coincided with the inhibition of cell migration and invasion in vitro, as well as a marked decrease in the expression of LASS2/TMSG1 probably through positive feedback.

  7. CerS2-knockdown via CRISPR-Cas9 technology in cultured colon epithelial cells impaired barrier function.

  8. Low expression of LASS2 and TGFB1 contributes to the aggressiveness and poor prognosis of hepatocellular carcinoma, and may represent a novel prognostic biomarker for hepatocellular carcinoma patients.

  9. ASGR1 can inhibit the activity of V-ATPase by interacting with LASS2, thereby suppressing the metastatic potential of hepatoma cells.

  10. These results suggest that the phosphorylation of ceramide synthases may be a key regulatory point in the control of the distribution and levels of sphingolipids of various acyl-chain lengths.

  11. Data show that 1-acylglycerol-3-phosphate O-acyltransferase 9 (AGPAT9) inhibit cell growth by regulating expression of KLF4/LASS2/V-ATPase proteins in breast cancer.

  12. these results indicate that miR-9 upregulation might be associated with malignant phenotype of bladder cancer. miR-9 promotes chemoresistance of bladder cancer cells by target LASS2.

  13. Data show that CERS2 expression was markedly different between various breast cancer cells and inversely correlated with cell invasion.

  14. silencing of TMSG1 increased V-ATPase activity, decreased extracellular pH and in turn the activation of secreted MMP-2, which ultimately promoted metastasis capacity of breast cancer cell.

  15. Results confirmed that TMSG1 is a potential metastasis suppressor gene, and suggested that the mechanism involved the induction of apoptosis and inhibition of cell proliferation via a caspase-dependent mitochondrial pathway.

  16. the vacuolar ATPase (V-ATPase) activity and extracellular hydrogen ion concentration were significantly decreased and the activity of secreted matrix metalloproteinase-2 (MMP-2) was downregulated in MCF-7 cells overexpressing LASS2/TMSG1

  17. the inhibitory effect of the LASS2 on growth, invasion and metastasis of prostate cancer cells

  18. Co-expression of CerS2 with CerS4/CerS6 reversed the inhibitory effect of long chain ceramides on cell proliferation and the induction of apoptosis. we detected no effect on cell proliferation.

  19. expression and role of ceramide synthase-2 in the lung

  20. results contribute to the conclusion that LASS2/TMSG1 could regulate V-ATPase activity and intracellular pH through the direct interaction of its homeodomain and the C subunit of V-ATPase

Mouse (Murine) Ceramide Synthase 2 (CERS2) interaction partners

  1. Our findings indicate that LASS2 plays an important role in the pathogenesis of diet-induced hepatic steatosis

  2. Gene expression analyses in livers of transgenic mouse mutants revealed that inactivation of CerS2 catalytic activity largely affects transcription of genes involved in lipid metabolism and cell division and is associated with the formation of hepatocellular carcinoma in 6 to 8-week-old mice.

  3. Deficiency of CerS2 influences intestinal barrier function and the severity of experimental colitis and may represent a potential mechanism for inflammatory bowel disease pathogenesis.

  4. LASS2 plays an important role in efficient liver regeneration in response to partial hepatectomy.

  5. Deletion of CerS2 strongly reduced very long-chain ceramides (Cer24:0, 24:1) but concomitantly increased long-chain ceramides and sphinganine in plasma and colon tissue. In naive CerS2(-/-) mice, the expression of tight junction proteins including ZO-1 was almost completely lost in the colon epithelium, leading to increased membrane permeability. Ceramide synthase 2 deficiency aggravates dextran induced colitis in mice.

  6. this study shows that Cers2 limits the levels of S1P in thymus and blood to maintain functional S1P gradients that mediate thymocyte emigration into the circulation

  7. that only LCBs, the substrates common for all of the CerS isoforms, but not ceramides and complex sphingolipids, were restored to the wild-type levels in the Cers2-rescued Cers1 mutant mouse brains.

  8. CerS1, -2, and -6 are hyperacetylated in the mitochondria of SIRT3-null mice.

  9. These results suggest that the phosphorylation of ceramide synthases may be a key regulatory point in the control of the distribution and levels of sphingolipids of various acyl-chain lengths.

  10. Haploinsufficiency for this enzyme altered the pattern of ceramide acylation in the liver without affecting total ceramide levels, replacing very-long-chain ceramides with long-chain C16-ceramides.

  11. Development of pheochromocytoma in ceramide synthase 2 null mice

  12. our data strongly indicate that G-CSF-induced CXCR2 expression is regulated in a CerS2-dependent manner and that CerS2 thereby promotes the migration of neutrophils, thus, contributing to inflammation and the development of EAE and MS.

  13. study is the first comparison of spatial distribution between SM molecular species and CerS isoforms, and revealed their distinct association in the brain.

  14. Data indicate that the augmented rate of death of ceramide synthase 2 (CerS2) null mice is due to elevated levels of tumor necrosis factor alpha (TNFalpha) secretion as a result of enhanced activity of TNFalpha-converting enzyme (TACE).

  15. CerS2-deficient kidneys were completely depleted of phytosphingosine-containing cortical sulfatides without any compensatio

  16. we first report that Lass2 deficiency caused the downregulation of miR-694 and the upregulation of its target gene Tnfaip3 in vivo in mice, which may be related to a high risk of occurrence of hepatocellular carcinoma

  17. The identification of specific cell types in which CerS2 protein is expressed is prerequisite to further mechanistic characterization of phenotypic abnormalities exhibited by CerS2-deficient mice.

  18. Lass2 is a protective gene against diethylnitrosamine-induced liver tumorigenesis; and upregulation of the TGF-beta1-Smad4-PAI-1 axis may contribute to the vulnerability of Lass2-knockout mice to diethylnitrosamine.

  19. Data indicate that oxidized phospholipids (OxPLs)-induced ceramide synthases (CerS1-Cers6) activity in macrophages is responsible for the accumulation of ceramide.

  20. Protection of a ceramide synthase 2 null mouse from drug-induced liver injury: role of gap junction dysfunction and connexin 32 mislocalization.

Ceramide Synthase 2 (CERS2) Antigen Profile

Antigen Summary

This gene encodes a protein that has sequence similarity to yeast longevity assurance gene 1. Mutation or overexpression of the related gene in yeast has been shown to alter yeast lifespan. The human protein may play a role in the regulation of cell growth. Alternatively spliced transcript variants encoding the same protein have been described.

Gene names and symbols associated with Ceramide Synthase 2 (CERS2) ELISA Kits

  • ceramide synthase 2 (CERS2) antibody
  • ceramide synthase 2 (Cers2) antibody
  • 0610013I17Rik antibody
  • AI225939 antibody
  • L3 antibody
  • Lass2 antibody
  • SP260 antibody
  • TMSG1 antibody
  • TRH3 antibody

Protein level used designations for Ceramide Synthase 2 (CERS2) ELISA Kits

LAG1 homolog, ceramide synthase 2 , LAG1 longevity assurance 2 , longevity assurance (LAG1, S. cerevisiae) homolog 2 , tumor metastasis-suppressor gene 1 protein , LAG1 longevity assurance homolog 2 , TRAM homolog 3 , longevity assurance homolog 2 , translocating chain-associating membrane protein homolog 3

GENE ID SPECIES
100055037 Equus caballus
29956 Homo sapiens
483187 Canis lupus familiaris
539223 Bos taurus
76893 Mus musculus
310667 Rattus norvegicus
100156737 Sus scrofa
Selected quality suppliers for Ceramide Synthase 2 (CERS2) ELISA Kits
Did you look for something else?